EntreMed Trying To Recapture Lost Mojo (ENMD)

Posted in pre-market 
April 13th, 2010

EntreMed, Inc. (NASDAQ: ENMD) is up big this morning on reports that it has initiated a Phase II study for its ENMD-2076 in ovarian cancer.  Investors should know that this stock has a history of being all over the place and has been around since the 1990′s as a public company.  It also used to be a $20, $20, $60, and even higher priced stock…

Shares are up 27% at $0.98 on right at 200,000 shares as of 8:47 AM EST.  Its average volume is only 201,000 shares and the stock’s 52-week trading range is $0.33 to $1.53.


Comments are closed